Siglec-1 (Sialoadhesin/CD169), expressed on myeloid cells, is a receptor for sialic acids that mediates adhesion to host cells and pathogens. However, certain pathogens exploit Siglec-1 binding for further dissemination and interfering with this binding may serve as potential therapeutic interventions. Here we identifi...
H. J. Brink, A. Affandi, S. Man et al.· Journal of Biological Chemis...· 0 citations
A capsid-targeting biological composed of a single-domain Llama VHH that binds CA, fused to human IgG1 Fc to activate TRIM21-mediated degradation results in inhibition of viral replication through TRIM21-mediated proteasome degradation of the HIV-1 capsid, establishing capsid-directed biologicals as therapeutic strateg...
Floor M. Stel, Charlotte E. J. Verkuijlen, Esther M. Zijlstra-Willems et al.· Communications Biology· 1 citation
Newly developed single-domain antibodies against Siglec-1 are used against Siglec-1 as a candidate inhibitor to limit HIV-1 transmission and support the development of host-directed nanobody-based strategies to reduce HIV-1 spread.
S. Man, A. Affandi, H. Brink et al.· Journal of Virology· 0 citations
The results demonstrate the broad neutralization potential of anti-capsid biologics with a high barrier to resistance, making capsid-targeting inhibitors important for novel antiretroviral drug strategies worldwide.
F. M. Stel, E. Zijlstra-Willems, A. van Nuenen et al.· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
